Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANASDAQ:GDTCNASDAQ:HILSNASDAQ:XTLB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$26.28$24.33M0.4124,701 shs237,144 shsGDTCCytoMed Therapeutics$2.32$2.33$1.20▼$4.05$25.38M-0.3178,594 shs473 shsHILSHillstream BioPharma$1.45-1.9%$1.34$0.19▼$2.65$25.56M3.081.39 million shs22,725 shsXTLBXTL Biopharmaceuticals$1.20+6.2%$3.99$0.92▼$3.05$6.16M1.1319,527 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%+11.30%-28.14%GDTCCytoMed Therapeutics0.00%+5.22%-1.49%-15.33%+16.00%HILSHillstream BioPharma-1.88%+6.97%-16.06%+1.55%-68.22%XTLBXTL Biopharmaceuticals0.00%+9.09%-23.08%-11.44%-53.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics1.2793 of 5 stars3.00.00.04.20.00.80.0GDTCCytoMed Therapeutics1.9368 of 5 stars3.53.00.00.03.30.00.0HILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AXTLBXTL Biopharmaceuticals0.2958 of 5 stars0.04.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 2.00Hold$36.00∞ UpsideGDTCCytoMed Therapeutics 3.00Buy$5.00115.52% UpsideHILSHillstream BioPharma 0.00N/AN/AN/AXTLBXTL Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00GDTCCytoMed Therapeutics$69.50K365.19N/AN/A$0.78 per share2.97HILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/A$0.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AGDTCCytoMed Therapeutics-$3.13MN/A0.00∞N/AN/AN/AN/AN/AHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/AXTLBXTL Biopharmaceuticals-$1.78MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/AXTLBXTL BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71GDTCCytoMed Therapeutics0.0421.54N/AHILSHillstream BioPharmaN/A3.013.01XTLBXTL BiopharmaceuticalsN/A0.81N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%GDTCCytoMed Therapeutics0.04%HILSHillstream BioPharma13.36%XTLBXTL Biopharmaceuticals4.40%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%GDTCCytoMed TherapeuticsN/AHILSHillstream BioPharma30.24%XTLBXTL Biopharmaceuticals29.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableGDTCCytoMed TherapeuticsN/A10.94 millionN/ANot OptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableXTLBXTL BiopharmaceuticalsN/A5.45 million3.87 millionNot OptionableXTLB, CARA, GDTC, and HILS HeadlinesRecent News About These CompaniesXTL Biopharmaceuticals names Noam Band as CEOApril 9, 2025 | uk.investing.comXTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive OfficerApril 8, 2025 | finanznachrichten.deXTL Biopharmaceuticals Appoints Noam Band as CEOApril 7, 2025 | tipranks.comXTL Names Mr. Noam Band as its New Chief Executive OfficerApril 7, 2025 | globenewswire.comXTL Biopharmaceuticals Reports Financial Results Amid Regional UnrestDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals Expands Portfolio with Social Proxy Acquisition Amidst Regional ChallengesDecember 30, 2024 | tipranks.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock, Short Interest ReportNovember 5, 2024 | benzinga.comXTL Biopharmaceuticals Ltd (XTLB)September 5, 2024 | investing.comXTL Biopharmaceuticals Ltd XTLBAugust 22, 2024 | morningstar.comXTL Biopharmaceuticals acquires AI firm Social ProxyAugust 16, 2024 | uk.investing.comXTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 MillionAugust 14, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. (XTLB.TA)July 22, 2024 | finance.yahoo.comXTL Entered Definitive Agreement to Acquire The Social ProxyJune 5, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd. ADRApril 26, 2024 | wsj.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%March 20, 2024 | msn.comUS Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top ViewsMarch 20, 2024 | msn.comDow Surges 350 Points; Fed Holds Rates SteadyMarch 20, 2024 | markets.businessinsider.comCrude Oil Surges 2%; Signet Jewelers Shares Spike HigherMarch 20, 2024 | markets.businessinsider.comXTL To Aquire The Social ProxyMarch 20, 2024 | globenewswire.comXTL Biopharmaceuticals Ltd ADR (XTLB)February 17, 2024 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? By Chris Markoch | May 14, 2025View U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? XTLB, CARA, GDTC, and HILS Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.CytoMed Therapeutics NASDAQ:GDTC$2.32 0.00 (0.00%) Closing price 05/30/2025 03:48 PM EasternExtended Trading$2.31 -0.01 (-0.65%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.Hillstream BioPharma NASDAQ:HILS$1.45 -0.03 (-1.88%) As of 05/30/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.XTL Biopharmaceuticals NASDAQ:XTLBXTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
